Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alexandra Jackovich
Observed name:
A. Jackovich
Institution:
Rutgers New Jersey Medical School
Observed institutions:
Rutgers, The State University of New Jersey,
University of Southern California,
USC Norris Comprehensive Cancer Center,
Rutgers New Jersey Medical School
ORCID:
0000-0002-8315-179X
Observed ORCID:
0000-0002-8315-179X
OpenAlex ID:
A5014258763
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma
2022
·
Sarmad Sadeghi
, David Quinn
, et al.
·
Journal of Clinical Oncology
·
23
651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
2021
·
S. Sadeghi
, D.I. Quinn
, et al.
·
Annals of Oncology
·
5
PDF
Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma
2024
·
Alexandra Jackovich
, Barbara J. Gitlitz
, et al.
·
Oncotarget
·
4
PDF
Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).
2024
·
Sarmad Sadeghi
, Nataliya Mar
, et al.
·
Journal of Clinical Oncology
·
2
Phase II trial of soluble EphB4-albumin in combination with PD-1 antibody (pembrolizumab) in relapsed/refractory head neck squamous cell carcinoma.
2021
·
Alexandra Jackovich
, Barbara J. Gitlitz
, et al.
·
Journal of Clinical Oncology
·
2
Moderate- to High-grade Blunt Liver and Spleen Injuries Warrant Repeat Imaging to Identify Treatable Complications: Results of the Radiographic Evaluation of Delayed Solid Organ Complications EAST Multicenter Trial
2025
·
Lindsey L. Perea
, Kelsey L. Fletcher
, et al.
·
Annals of Surgery
·
1
EphrinB2: Expression of a novel potential target in renal cell carcinoma
2023
·
Chhavi Gupta
, Akash Pramod Sali
, et al.
·
Indian Journal of Urology
·
1
EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy
2020
·
Chhavi Gupta
, Akash Sali
, et al.
·
Pathology - Research and Practice
·
1
EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).
2023
·
Sarmad Sadeghi
, Imran Siddiqi
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
9
Citation count:
39
H-index:
3
I10-index:
1
Year
Topic
Type